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Stem Cell Transplantation and GVHD Development
Yuri Fedoriw,1,2 T. Danielle Samulski,2
Allison M. Deal,3,4 Cherie H. Dunphy,1,2 Andrew Sharf,4
Thomas C. Shea,2,4,5 Jonathan S. Serody,2,4,5 Stefanie Sarantopoulos2,4,5Patients without chronic graft-versus-host disease (cGVHD) have robust B cell reconstitution and are able to
maintain B cell homeostasis after allogeneic hematopoietic stem cell transplantation (HSCT). To determine
whether B lymphopoiesis differs before cGVHD develops, we examined bone marrow (BM) biopsies for ter-
minal deoxynucleotidyl transferase (TdT) and PAX5 immunostaining early post-HSCTat day 30 when all pa-
tients have been shown to have high B cell activating factor (BAFF) levels. We found significantly greater
numbers of BM B cell precursors in patients who did not develop cGVHD compared with those who devel-
oped cGVHD (median5 44 vs 2 cells/high powered field [hpf]; respectively; P\.001). Importantly, a signif-
icant increase in precursor B cells was maintained when patients receiving high-dose steroid therapy were
excluded (median 5 49 vs 20 cells/hpf; P 5 .017). Thus, we demonstrate the association of BM B cell pro-
duction capacity in human GVHD development. Increased BM precursor B cell number may serve to predict
good clinical outcome after HSCT.
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In the absence of B cell activating factor (BAFF),
normal B cell homeostasis in murine models is not
possible [1]. Early after hematopoietic stem cell trans-
plantation (HSCT), patients have high BAFF levels,
suggesting its vital role in human B cell reconstitution
[2]. Patients who have undergone HSCT have de-
creased total B cells, including memory B cells, associ-
ated with immune deficiency and increased infection
[3-6]. Studies of excess BAFF in chronic graft-versus-
host disease (cGVHD) revealed that a previously
described supernormal ‘‘surge’’ in na€ıve B cell number
after HSCT [7-9] accounted for significantly lower
BAFF/B cell ratios and decreased B cell auto-
reactivity [2,10]. Thus, akin to what has been
demonstrated in mouse models of autoimmunity,
a peripheral na€ıve B cell compartment is critical for
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Furthermore, only those patients with cGVHD able
to robustly recover na€ıve B cell compartments after
targeted B cell depletion demonstrate clinical
improvement [10,14]. Whether recovery of B cell
homeostasis after HSCT is due to B lymphopoiesis
in the bone marrow (BM) remains unclear [15,16].
Increased BM precursor B cell numbers have been
found after HSCT [17], but examinations of BM
aspirates in GVHD have been inconclusive [15]. De-
creased frequency of B cell precursors in BM aspirates
using flow cytometry before, during, and after devel-
opment of acute GVHD (aGVHD) and cGVHD
have been observed, but given the variability of sample
cellularity and composition, these studies are difficult
to interpret [15,18,19]. Additionally, in a murine
model, the hematopoietic niche that was vital for B
lymphopoiesis was altered when GVHD was present,
further suggesting that examination of BM core
biopsies from patients before GVHD development
was warranted [20].We report a B cell-specific BMdif-
ference after HSCT that will instruct future studies of
GVHD pathophysiology. If further studies confirm
our findings, increased BM precursor B cell number
may serve as a predictive marker of good clinical out-
come after HSCT.MATERIALS AND METHODS
BM samples were collected on a protocol approved
by the Institutional Review Board at The University of
NorthCarolina. From January 2010 toMarch 2011, we
identified 30 patients actively being followed in the BM
Transplant Clinic who were at least 12 months post-
peripheral blood allogeneic HSCT (median 5 29
months), hadno evidence of active or relapsinghemato-
logic malignancy, and for whom routine ‘‘day 30’’ post-
transplant biopsies were available for evaluation. No
patients receiving BM grafts were identified in this
group. Five hundred cell differential counts were per-
formedonWright-Geimsa stainedBMaspirate smears,
and the corresponding hematoxylin and eosin stained,
formalin fixed, and paraffin-embedded biopsy sections
were reviewed for marrow cellularity and distribution
of hematopoietic elements. To identify precursor B
cells, tissue sections were stained by immunohisto-
chemistry for terminal deoxynucleotidyl transferase
(TdT), a marker of primarily early lymphoid progeni-
tors, PAX5, a B cell lineage specific antigen, and
CD3, a pan-T cell marker (all antibodies: Leica-
Microsystems, Wetzler, Germany). Positive-staining
cells were enumerated based on a method previously
published [17]. Briefly, after antibody validation, two
independent observers blinded to clinical history
counted the number of positive-stained cells per 600
high powered field (hpf) in areas representative of BM
cellularity and distribution. The frequency of positive-stained cells per 500-total nucleated cells was also
determined. Eleven patients with untreated lymphoma
without marrow involvement or other abnormalities
and who had not undergone HSCT (‘‘No HSCT’’)
served as reference samples.Descriptive statistics are re-
ported as medians, with ranges or percentages where
appropriate. Comparisons between groups were made
for continuous variables usingWilcoxon rank sum tests
and Fisher Exact tests for categorical variables.RESULTS
Thirty patients being actively followed in the clinic
had been followed for a median of 898 days after
HSCT. Fifteen of the 30 patients developed cGVHD
(a median of 233 days [range, 127-799 days] after
HSCT), and 15 never developed cGVHD (a median
follow-up of 853 days [range, 370-2051 days] after
HSCT). A thorough secondary pathology review was
performed to confirm cancer remission in all patients.
With respect to the 8 cases of B cell lymphoma/leuke-
mia, all of 8 patients had confirmation of normal and/
or donor karyotype by cytogenetic analysis and 6 of 8
patients underwent flow cytometry of BM aspirate to
confirm the B cells measured by PAX5 were not due
to relapsing disease. Clinical characteristics are pre-
sented in Table 1. All patients were receiving tacroli-
mus or tacrolimus plus ‘‘mini-dose’’ methotrexate;
some also received anti-thymocyte globulin (ATG)
or alemtuzumab for aGVHD prophylaxis. Five of the
study patients were treated with alemtuzumab before,
or at the time of BM evaluation. These patients are dis-
tributed approximately equally in all groups analyzed
(3 without cGVHD, 2 with cGVHD). Although the
numbers of treated individuals is not sufficient to
draw independent and significant conclusions with re-
spect to alemtuzumab effect, the median number of
TdT1 cells per hpf was 42 with a range of 2 to 62
that was notably not different from the patients not
treated with alemtuzumab (P 5 .60). Nine of the pa-
tients who developed cGVHD and 3 of the patients
who never developed cGVHD were receiving high-
dose steroids for aGVHD at the time of BM evaluation
(median days of steroid therapy before biopsy 5 12.5
vs 11, respectively). All patients who developed
cGVHD had at least grade II aGVHD, but impor-
tantly, at day 30, there were 6 patients who later devel-
oped cGVHD, but at day 30, BM biopsy showed no
evidence of aGVHD and the patients were not receiv-
ing steroids. ‘‘Day 30’’ posttransplant peripheral blood
and BM findings are summarized in Table 2. Unfrac-
tionated and CD31 T cell donor chimerism and over-
all BM cellularity were not different between cGVHD
and no cGVHD groups. The median time to periph-
eral neutrophil engraftment was not different, and
the day 30 peripheral blood lymphocyte, monocyte,
and platelet counts did not differ significantly between
Table 1. Clinical Characteristics of Patients atDay 30with (+)
or without (2) Future cGVHD
Characteristic 2cGVHD +cGVHD P Value
No. of patients 15 15
Median age, years (range) 56 (18-67) 39 (20-67) .70
Sex, no. of men (%) 9 (60) 9 (60) 1
Female donor to male
recipient (%)
1 (7) 2 (13) 1
Conditioning regimen (%)
Myeloablative 6 (40) 7 (47) 1
Nonmyeloablative 9 (60) 8 (53)
Source of graft (%)
Peripheral blood 15 (100) 15 (100) 1
HLA matching (%)
Matched, unrelated 8 (53) 8 (53) 1
Matched, related 7 (47) 7 (47)
GVHD prophylaxis (%)
Tac vs Tac + MTX 6 (40) 6 (40) 1
ATG 6 (40) 7 (47) 1
Alemtuzumab 3 (20) 2 (13) 1
Follow-up, days (range) 853 (370-2051) 910 (365-2178) .90
Disease (%)
AML 3 (20) 5 (33) .50
AML from MDS 2 (13) 0 (0)
MDS 1 (7) 2 (13)
CML 1 (7) 2 (13)
CMML 1 (7) 0 (0)
PV 1 (7) 0 (0)
Primary myelofibrosis 0 (0) 1 (7)
AA 0 (0) 2 (13)
ALL 2 (13) 1 (7)
MCL 0 (0) 1 (7)
DLBCL 1 (7) 0 (0)
FL 2 (13) 0 (0)
CLL/SLL 0 (0) 1 (7)
Hodgkin lymphoma 1 (7) 0 (0)
Time to neutrophil
engraftment, days
15 (12-22) 14 (11-20) .40
Grades II-IV aGVHD* (%) 2 (13) 9 (60) <.0001
cGVHD indicates chronic graft-versus-host disease; Tac, tacrolimus;
MTX, methotrexate; ATG, anti-thymocyte globulin; AML, acute myeloid
leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous
leukemia; CMML, chronic myelomonocytic leukemia; PV, polycythemia
vera; AA, aplastic anemia; ALL, acute lymphoblastic leukemia; MCL,
mantle cell lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follic-
ular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lympho-
cytic lymphoma; aGVHD, acute graft-versus-host disease.
*At the time of bone marrow evaluation.
Table 2. BM and Peripheral Blood Findings in Patient 30
Days after HSCT with (+) or without (2) Future cGVHD
Development
Characteristic 2cGVHD +cGVHD P value
No. of patients 15 15
Day of BM evaluation after
transplantation
30 (28-44) 31 (30-39) .30
Peripheral blood
WBC ( 103/mL) 5.4 (2.7-13.1) 6.7 (2.9-27.6) .04*
Neutrophils 3.5 (1.5-12.1) 5.6 (2.2-25.7) .02*
Lymphocytes 0.6 (0.3-1.2) 0.5 (0.1-1.3) .09
Monocytes
Hemoglobin (g/dL) 11.6 (8.9-13.5) 11.4 (8.5-13.4) .50
Platelets ( 103/mL) 124 (29-282) 111 (23-231) .30
BM Cellularity (%) 45 (30-90) 50 (30-80) .60
Chimerism studies
>95% of total cells donor (%) 15 (100) 14 (93) 1
>95% of T cells donor (%) 4 (31) 4 (31) 1
BM cellularity (%) 50 (30-80) 45 (30-90) .60
IHC counts (per 600 hpf)
TdT 44 (1-78) 2 (0.5-41) .0007
PAX5 35 (1-101) 8 (0.5-106) .008*
CD3 11 (1-33) 15 (1-54) .40
N† 14 14
BM aspirate differential (%)
Blasts 2 (1-9) 2 (0-3) .50
Promyelocytes 1 (1-4) 2 (0-7) .40
Myelocytes 7 (2-12) 8 (5-15) .60
Maturing granulocytes 43 (21-59) 43 (11-53) .40
Erythrocytes 33 (19-49) 28 (7-56) .90
Lymphocytes 8 (1-25) 6 (1-20) .40
Monocytes 3 (0-6) 2 (0-5) .20
Eosinophils 5 (0-13) 5 (0-14) .90
Plasma cells 1 (0-3) 1 (0-5) .80
BM indicates bone marrow; HSCT, hematopoietic stem cell transplanta-
tion; cGVHD, chronic graft-versus-host disease; IHC, immunohisto-
chemical; hpf, high powered field; TdT, terminal deoxynucleotidyl
transferase.
IHC counts indicate enumeration by immunohistochemical analysis de-
scribed in the methods section.
*Not significant after exclusion of steroid treated group.
†One case from each of the groups did not have a bone marrow aspirate
available for evaluation.
970 Biol Blood Marrow Transplant 18:958-973, 2012Y. Fedoriw et al.cGVHD and the steroid-treated groups. The total pe-
ripheralWBC count was higher in the cGVHDgroup,
owing primarily to the increased neutrophil counts
(median 5 5.6  103/mL vs 3.5  103/mL; P 5 .02).
However, the difference was not significant after ex-
clusion of steroid therapy (WBC 5 6.5  103/mL vs
4.8  103/mL; P 5 .40; neutrophils 5 4.9  103/mL
vs 3.3  103/mL; P 5 .20). Total marrow cellularity
and cellular composition in associated BM aspirates
did not differ between patients who developed or did
not develop cGVHD. Thus, cells in the BM aspirates
at day 30 did not differ significantly in patients who
later developed cGVHD.
Whereas manual aspirate differential counts irre-
spective of concurrent steroid therapy were not differ-
ent, B and T cell-specific markers, along with TdT
staining, highlighted significant differences in theabsolute numbers of precursor B cells (Figure 1A). Al-
though TdT expression is not lineage-specific, B cell
precursors represent the vast majority of the TdT1
pool in the BM [21], and analysis of sequential sections
also demonstrated correlation of PAX5 and TdT
staining distribution. TdT1 cells were increased in
all patients early after HSCT. Consistent with previ-
ous analyses of healthy BM, the reference group had
similarly rare lymphoid precursors [17]. Notably, pa-
tients who did not develop cGVHD had significantly
higher precursor B cell numbers relative to patients
who later developed cGVHD (median 5 44 vs 2
cells/hpf; P 5 .0007). Patients with prior receipt of
ATG or alemtuzemab for aGVHD prophylaxis were
equally distributed between the no cGVHD and
cGVHD groups (Table 1) and these patients did not
have lower precursor B cell numbers compared to un-
treated patients (data not shown). Patients receiving
high-dose steroids at the time of biopsy had low abso-
lute numbers of precursor B cells (Figure 1B), likely
due to steroid-induced apoptosis [22]. Six of the 15
Figure 1. Morphologic and immunohistochemical analysis of day-30 post-hematopoietic stem cell transplantation (HSCT) bone marrow (BM) bi-
opsies in patients who never developed or who developed chronic graft-versus-host disease (cGVHD). (A) Representative micrograph of terminal
deoxynucleotidyl transferase (TdT) immunohistochemical staining in patients who never developed (‘‘No cGVHD’’) or who subsequently developed
cGVHD (‘‘Yes cGVHD’’). (B) Absolute numbers of TdT1 BM B cell precursors in patients who never developed (2) vs those who later developed
(1) cGVHD, in relation to steroid therapy at the time of BM evaluation (1 vs 2 steroid). Reference BM (‘‘No HSCT’’) showed significantly fewer
precursors compared to the 1 or 2 cGHVD group after steroid effect was excluded (*P 5 .03 and P\ .01, respectively). (C) Representative mi-
crograph or PAX5 immunohistochemical staining in patients who never developed (‘‘No cGVHD’’) or who develop cGVHD (‘‘Yes cGVHD’’). (D)
Total BM B cell number as determined by PAX5 staining in patients who never developed (2) vs those who developed (1) cGVHD, currently
(1), or never treated with (2) steroids. Compared to the reference samples (‘‘No HSCT’’), total B cell numbers were similar between patients
who had undergone HSCT; NS indicating not significant. (E) Representative micrograph of CD3 immunohistochemical staining in patients who never
developed (‘‘No cGVHD’’) or who develop cGVHD (‘‘Yes cGVHD’’). (F) Absolute CD31 T cell number in patients who never developed (2) or
developed (1) cGVHD, either treated with (1) steroids or never treated with (2) steroids. Reference BM (‘‘No HSCT’’) showed significantly
more CD31 T cells compared to the 1 or 2 cGVHD group after steroid therapy was excluded (*P 5 .04 and P\ .01, respectively). Description
of patient groups: 2cGVHD (total n 5 15): patients who never developed cGVHD including those who received steroid treatment for acute GVHD
(aGVHD; n 5 3) and patients who were not receiving steroid treatment at the time of BM biopsy (n 5 12), followed for a total median of 792 and
980 days, respectively. 1cGVHD (total n 5 15): patients who developed GVHD (n 5 15) receiving high-dose steroids ($0.5 mg/kg; n 5 9) vs those
without steroid therapy from time of HSCT to time of BM biopsy (n 5 6), followed for a total median of 630 and 1100 days, respectively. No HSCT
(total n511): Age and gender-matched reference biopsies from untreated patients with non-Hodgkin lymphoma (NHL; diffuse large B cell lymphoma
[n 5 7]; low-grade NHL [n 5 2], follicular lymphoma, grade 3 [n 5 1], classic Hodgkin lymphoma [n 5 1]) who underwent staging BM evaluation.
For all micrographs, the original magnification was 600. Box and whisker plots express the median, 25th and 75th percentile at the ends of the box,
and 5th and 95th percentile at the ends of the whiskers.
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tion of Figure 1B, had no aGVHDor steroid treatment
before the BM biopsy. Importantly, the group with
a significantly decreased B cell precursor number with-
out aGVHD or steroid treatment at the time of analy-
sis (n 5 6), later developed cGVHD (Figure 1B).
Patients who never developed cGVHD had signifi-
cantly higher BM precursor B cell numbers compared
with those who later developed cGVHD (median5 49
vs 20 cells/hpf; P5 .0170; Figure 1B). Thus, the pres-
ence of B cell precursors early after HSCT correlated
with decreased incidence of GVHD after HSCT.
A similar pattern of PAX5 to TdT staining
was found in patients who underwent HSCT
(Figure 1C). Patients who did not develop cGVHD,
had higher numbers of B cells relative to those who de-
veloped cGVHD, but no significant differences in to-
tal B cell numbers were appreciated after accounting
for steroid effect (Figure 1D). The absolute numbers
of CD31 T cells was not different with respect to fu-
ture cGVHD status (Figure 1E). Exclusion of steroid
therapy had no impact on BMT cell numbers in either
group (Figure 1F). Thus, taken together, we have
found that the BM difference between patients who
later develop cGVHD was B cell specific.DISCUSSION
Having previously demonstrated the importance
of B cell homeostasis and BAFF in GVHD [2,10], we
aimed to determine whether BM B lymphopoiesis
contributed to cGVHD development. Because high
plasma BAFF levels are found in all patients 30 days
post-HSCT (at day 30), we studied the BM at this
time point, when B cell recovery, not yet apparent by
peripheral blood testing, was likely occurring in the
BM. We found that B cell precursors were increased
in patients who never developed cGVHD. Although
steroid therapy had a dramatic effect on B lymphopoi-
esis, significant difference in precursor numbers was
evident after the exclusion of steroid therapy. Thus, al-
though steroid therapy is associated with quantifiable
and dramatic suppression of B lymphopoiesis in the
BM, failure to robustly produce pre-B cells in the
marrow in cGVHD could not be explained by steroid
effect alone. This finding is consistent with previous
work showing that patients without altered B cell
homeostasis avert B cell autoimmunity [2,10].
All patients in our cohort who subsequently
developed cGVHD had previous aGVHD, although
aGVHD had not yet developed in 6 of these cases by
the time of BM evaluation. The data from our study
cannot entirely confirm the loss of the B precursor
pool as an independent consequence of cGVHDalone.
However, aGVHD is a risk factor for cGVHD [23-25]
and our data, taken together with previous findings,suggest diminished B lymphopoiesis is related to
cGVHD development. The systemic inflammatory T
cell response typifying aGVHD may promote an
environment ineffective for B lymphopoiesis and
permissive for subsequent development of human
cGVHD [26].
Because B lymphopoiesis after HSCT, in the con-
text of active transitioning into the periphery and sec-
ondary lymphoid organs, is highly relevant to B cell
autoimmunity, total BM B cells of all maturational
stages, stainedwithPAX5,were also enumerated.Total
B cell number was increased in patients who never de-
veloped cGVHD relative to those who did (median 5
35 vs 8 cells/hpf; P 5 .008). However, as the pattern
of PAX5 staining was similar compared toTdT, largely
owing to the TdT1 pool, the difference was not signif-
icant after exclusion of steroid therapy (41.5 vs 16 cells/
hpf; P5 .10). Together, these data corroborate a more
dynamic process of B cell development and transition
after HSCT. Importantly, differences in BM produc-
tion were B cell specific, as the T cell number was not
associated with the development of aGVHD or
cGVHD and irrespective of steroid therapy.
Together, our data reveal that the difference in pe-
ripheral B cell composition found in GVHD relates to
BM production capacity. Although pathologic produc-
tion of BAFF is found in cGVHD [27], physiologic
BAFF, as it relates to BM B lymphopoiesis early after
myeloablation or B cell depletion, is crucial for B cell
homeostasis [1,9,28]. Thus, future research in GVHD
prophylaxis and pathophysiology should focus on B
lymphopoiesis and the BM niche.ACKNOWLEDGMENTS
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